Analysis of Revenues
Paying users area
Try for free
AstraZeneca PLC pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
The data is hidden behind: . Unhide it.
Get 1-month access to AstraZeneca PLC for $22.49, or
get full access to the entire website for at least 3 months from $62.19.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
AstraZeneca PLC, income statement, revenues
US$ in millions
| 12 months ended: | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceuticals | |||||||||||
| External revenue |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
| Item | Description | The company |
|---|---|---|
| External revenue | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | AstraZeneca PLC external revenue decreased from 2012 to 2013 but then slightly increased from 2013 to 2014. |